Showing 861-870 of 8908 results for "".
Hair Loss in Patients With Diverse Skin Tones (Part 2)
https://practicaldermatology.com/programs/practical-dermatology/hair-loss-in-patients-with-diverse-skin-tones-part-2/18195/In this second installment of a two-part episode of The Practical Dermatology Podcast, Brooke Jackson, MD, founder and owner of Skin Wellness Dermatology Associates in Durham, NC, and a dermatologic surgeon and dermatologist, continues the conversation, focusing on different hair textures and stylesPractical Dermatology Roundtable: Generalized Pustular Psoriasis, Ch. 2
https://practicaldermatology.com/programs/the-practical-dermatology-roundtable/practical-dermatology-roundtable-generalized-pustular-psoriasis-ch-2/32758/Host Neal Bhatia, MD, FAAD, and guests Laura K. Ferris, MD, PhD, FAAD, and Jason E. Hawkes, MD, MS, FAAD, discuss the differences between psoriasis subtypes, the importance of a specialized therapeutic approach targeting the IL-36 pathway for generalized pustular psoriasis, and the role of neutrophiNew Drugs Helping AD Catch Up to Psoriasis
https://practicaldermatology.com/series/updates-atopic-dermatitis/new-drugs-helping-ad-catch-psoriasis/28650/Dr. H.L. Greenberg, a board-certified dermatologist and founder of Las Vegas Dermatology®, talks with Practical Dermatology about some of the new drugs that are helping atopic dermatitis catch up to psoriasis in terms of available therapeutics.DWTV Extra: Phase 3 Data on Roflumilast for AD, PsO
https://practicaldermatology.com/programs/practical-dermatology/dwtv-extra-phase-3-data-on-roflumilast-for-ad-pso/35925/Study investigator Melinda Gooderham, MD, talks about the Phase 3 trials of roflumilast cream 0.15% for adults and children down to age 6 with atopic dermatitis and roflumilast foam 0.3% for patients older than 12 with psoriasis of the scalp and body.Skin Cancer Perceptions, Cimzia for Psoriasis, Eczema and CV Risk
https://practicaldermatology.com/topics/psoriasis/dermwire-tv-skin-cancer-perceptions-cimzia-for-psoriasis-eczema-and-cv-risk/18301/A new national survey, Skin Cancer In America 2018, conducted by Health Union, explores perceptions of patients with skin cancer. Cimzia (certolizumab pegol, UCB) has received FDA approval for treatment of adults with moderate to severe plaque psoriasis. Cimzia is the first Fc-free, PEGylated anti TRadiesse Plus Launches, AAD Convenes, NPF Registry Begins
https://practicaldermatology.com/topics/psoriasis/dermwiretv-radiesse-plus-launches-aad-convenes-npf-registry-begins--epesurag/18939/In this edition of DermWireTV: Merz Aesthetics launches Radiesse Plus with lidocaine for the treatment of facial wrinkles and folds and the National Psoriasis Foundation (NPF) launches new patient registry focused on patient safety. Plus, updates from the annual meeting of the American Academy of De"Best Practices in the Treatment of Acne" Drs. Harper and Stein-Gold
https://practicaldermatology.com/youngmd-connect/ymdc-workshops/best-practices-in-the-treatment-of-acne-drs-harper-and-stein-gold/24543/Expert dermatologists Drs. Linda Stein Gold and Julie Harper share their insights on treating acne across all severities. Join their discussion with YoungMD Connect members for valuable experiences and practice pearls. To access the full video and more, become a YoungMD Connect member for free 90-daDERM2020 Attendee Reaction: Emmanual Agnant, PA-C
https://practicaldermatology.com/conferences/dermatology-education-foundation-derm-2020/derm2020-attendee-reaction-emmanual-agnant-pa-c/19838/Emmanual Agnant, PA-C from Bronx, NY shares his thoughts on participating in DERM2020.Should I Recommend Products that Claim to Contain Probiotics?
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/should-i-recommend-products-that-claim-to-contain-probiotics/19829/The language of the microbiome can be confusing. Dr. Friedman prefers to focus on symbiotics when making topical product recommendations.Allergan Acquires Vitae, PsA Day, Novan News
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-allergan-acquires-vitae-psa-day-novan-news/18572/Allergan is acquiring clinical-stage biotechnology company Vitae Pharmaceuticals for $21.00 per share, in cash, for a total transaction value of approximately $639 million. Novan has launched its initial public offering and is now listed on the NASDAQ. Celgene Corporation and the National Psoriasis